This study showed the different changes of EGFR mutations detected by plasma circulating tumor DNA (ctDNA) after EGFR-TKI targeted therapy which could predict the different prognosis of NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.